Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunochemotherapy with Capecitabine, IL-2, IFN-alpha, and Vinblastine in MRCC
NCT00226798Phase 2Unknown
- Sponsor
- Rambam Health Care Campus
- Start
- Dec 2003
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in metastatic renal cell carcinoma (mRCC), sponsored by Rambam Health Care Campus. Status: unknown.
02
Drugs
capecitabine
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT00226798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00226798.